Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer-Reference-Cited by-同舟云学术

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

Published:2006-11-02 Issue:18 Volume:355 Page:1851-1862
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Poole Christopher J.,Earl Helena M.,Hiller Louise,Dunn Janet A.,Bathers Sarah,Grieve Robert J.,Spooner David A.,Agrawal Rajiv K.,Fernando Indrajit N.,Brunt A. Murray,O'Reilly Susan M.,Crawford S. Michael,Rea Daniel W.,Simmonds Peter,Mansi Janine L.,Stanley Andrew,Harvey Peter,McAdam Karen,Foster Liz,Leonard Robert C.F.,Twelves Christopher J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa052084

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial;The Lancet Oncology;2023-12

2. Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment;Cancer Medicine;2023-08-08

3. Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know;Reviews in Cardiovascular Medicine;2023-05-18

4. Chemotherapy;Medicines for Cancer;2023

5. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency;Pharmaceutics;2022-11-30